Monitoring of treatment responses and clonal evolution of tumor cells by circulating tumor DNA of heterogeneous mutant EGFR genes in lung cancer

Lung Cancer

Volumn 94, Issue , 2016, Pages 68-73

  Imamura, Fumio ^a   Uchida, Junji ^a   Kukita, Yoji ^a   Kumagai, Toru ^a   Nishino, Kazumi ^a   Inoue, Takako ^a   Kimura, Madoka ^a   Oba, Shigeyuki ^b   Kato, Kikuya ^a  

^a OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

EGFR; Evolution; Lung cancer; Mutation; T790M

Indexed keywords

CIRCULATING TUMOR DNA; DNA; ERLOTINIB; GEFITINIB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CIRCULATING TUMOR CELL; CLONAL EVOLUTION; FEMALE; GENE MUTATION; GENETIC HETEROGENEITY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT RESPONSE; TUMOR BIOPSY; VERY ELDERLY; BLOOD; EXON; GENETICS; LUNG NEOPLASMS; MUTATION; PATHOLOGY; PROGNOSIS; TREATMENT OUTCOME; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS; CLONAL EVOLUTION; DNA, NEOPLASM; EXONS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MUTATION; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 84960423132     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2016.01.023     Document Type: Article

References (22)

1. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004, 350:2129-2139.
2. Maemondo M., Inoue A., Kobayashi K., Sugawara S., Oizumi S., Isobe H., et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 2010, 362:2380-2388.
3. Rosell R., Carcereny E., Gervais R., Vergnenegre A., Massuti B., Felip E., et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012, 13(3):239-246.
4. Kobayashi S., Boggon T.J., Dayaram T., Jänne P.A., Kocher O., Meyerson M., et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2005, 352:786-792.
5. Chaft J.E., Oxnard G.R., Sima C.S., Chaft J.E., Oxnard G.R., Sima C.S. Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design. Clin. Cancer Res. 2011, 17(19):6298-6303.
6. Nishino K., Imamura F., Morita S., Mori M., Komuta K., Kijima T., et al. A retrospective analysis of 335 Japanese lung cancer patients who responded to initial gefitinib treatment. Lung Cancer 2013, 82(2):299-304.
7. Gerlinger M., Rowan A.J., Horswell S., Larkin J., Endesfelder D., Gronroos E., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 2012, 366(10):883-892.
8. Zhang J., Fujimoto J., Zhang J., Wedge D.C., Song X., Zhang J., et al. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science 2015, 346:256-259.
9. Schwarzenbach H., Hoon D.S., Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat. Rev. Cancer 2011, 11:426-437.
10. Diehl F., Schmidt K., Choti M.A., Romans K., Goodman S., Li M., et al. Circulating mutant DNA to assess tumor dynamics. Nat. Med. 2008, 14:985-990.
11. Jiang T., Ren S., Zhou C. Role of circulating-tumor DNA analysis in non-small cell lung cancer. Lung Cancer 2015, 90:128-134.
12. Taniguchi K., Uchida J., Nishino K., Kumagai T., Okuyama T., Okami J., et al. Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas. Clin. Cancer Res. 2011, 17(24):7808-7815.
13. Kukita Y., Uchida J., Oba S., Nishino K., Kumagai T., Taniguchi K., et al. Quantitative identification of mutant alleles derived from lung cancer in plasma cell-free DNA via anomaly detection using deep sequencing data. PLoS One 2013, 8(11):e81468.
14. Uchida J., Kato K., Kukita Y., Kumagai T., Nishino K., Daga H., et al. Diagnostic accuracy of noninvasive genotyping of EGFR in lung cancer patients by deep sequencing of plasma cell-free DNA. Clin. Chem. 2015, 61(9):1191-1196.
15. Bai H., Mao L., Wang H.S., et al. Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer. J. Clin. Oncol. 2009, 27:2653-2659.
16. Oxnard G.R., Paweletz C.P., Kuang Y., Mach S.L., O'Connell A., Messineo M.M., et al. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin. Cancer Res. 2014, 20(6):1698-1705.
17. Inukai M., Toyooka S., Ito S., Asano H., Ichihara S., Soh J., et al. Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. Cancer Res. 2006, 66(16):7854-7858.
18. Su K.Y., Chen H.Y., Li K.C., Kuo M.L., Yang J.C., Chan W.K., et al. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J. Clin. Oncol. 2012, 30(4):433-440.
19. Oxnard G.R., Arcila M.E., Chmielecki J., Ladanyi M., Miller V.A., Pao W. New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Clin. Cancer Res. 2011, 17(17):5530-5537.
20. Sakamoto H., Shimizu J., Horio Y., Ueda R., Takahashi T., Mitsudomi T., et al. Disproportionate representation of KRAS gene mutation in atypical adenomatous hyperplasia, but even distribution of EGFR gene mutation from preinvasive to invasive adenocarcinomas. J. Pathol. 2007, 212(3):287-294.
21. Wang Z., Chen R., Wang S., Zhong J., Wu M., Zhao J., et al. Quantification and dynamic monitoring of EGFR T790M in plasma cell-free DNA by digital PCR for prognosis of EGFR-TKI treatment in advanced NSCLC. PLoS One 2014, 9(11):e110780.
22. Schwarzenbach H., Hoon D.S., Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat. Rev. Cancer 2011, 11(6):426-437.